Skip to main content

Normal Saline for Parenteral Use Market to Hit USD 3.71 Billion by 2026; Increasing Demand for Effective Fluid Solutions for Admitted Patients to Fuel Growth: Fortune Business Insights™

Pune, India, Jan. 11, 2021 (GLOBE NEWSWIRE) — The global normal saline for parenteral use market size is projected to reach USD 3.71 billion by 2026, exhibiting a CAGR of 5.4% during the forecast period. Increasing prevalence of diarrhea worldwide will be a prominent growth driver for this market, shares Fortune Business Insights™ in its report. According to the World Health Organization (WHO), diarrhea is the second leading cause of death in children under five years of age, killing around 525,000 children under five every year. The WHO estimates that there are approximately 1.7 billion cases of childhood diarrhea each year, globally.Diarrhea lasts for several days and depletes the body’s water and mineral resources, leaving the patient severely dehydrated. The complications can get aggravated in children whose bodies cannot withstand the effects of such diseases. Normal saline for parenteral use is the quickest and the most efficient way of injecting a diarrheal patient’s body with the necessary fluids and prevent imminent death. Saline, which is 0.9% sodium chloride solution, contains the essential ingredients required to reboot a dehydrated body and is thus widely used in healthcare facilities around the world.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/normal-saline-for-parenteral-use-market-104520
Cancelation of Surgeries amid COVID-19 to Negatively Impact the MarketWith coronavirus cases continuing their upward spiral across the globe, the provision of surgical services, especially elective ones, has plunged. A 120-country research initiative, led by the University of Birmingham, called the CovidSurg Collaborative estimates that nearly 28.4 million elective surgeries worldwide are likely to get canceled or deferred in 2020. This will mainly be a result of governments redirecting their medical and health resources towards treating COVID-19 patients and preventing hospitals from getting overwhelmed with the escalating number of infections.In the UK, for example, the National Health Service (NHS) issued a directive in April to hospitals that led to the cancelation of over 2.1 million routine surgeries across the country, as the NHS prepared to tackle the impending coronavirus peak. The steep decline in surgeries has led to considerable revenue shortfalls for market companies, impacting the market growth of normal saline for parenteral use. For example, ICU Medical’s gross profit in the third quarter of 2020 was 36% as compared to 39% in 2019.
Click here to get the short-term and long-term impact of COVID-19 on this market.Please visit: https://www.fortunebusinessinsights.com/normal-saline-for-parenteral-use-market-104520
Robust Healthcare Facilities to Bolster North America’s Leading Market PositionAt USD 1.10 billion, North America dominated the normal saline for parenteral use market share in 2019 and is expected to retain its commanding position throughout the forecast period. This will be mainly because of the strong and well-established healthcare infrastructure in the US and Canada. Manufacturers in the region have also been aggressively expanding their production capacities to cater to the growing demand for saline owing to the increasing number of inpatient hospital admissions.In Asia Pacific, the primary growth determinants for the market are the rapidly expanding patient population and improving healthcare facilities. Strong support from regulatory authorities in the European Union (EU) will aid market growth in Europe.
Quick Buy –  Normal Saline for Parenteral Use Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/104520
Supportive Regulatory Climate for Novel Solutions to Stoke InnovationKey players in this market are capitalizing on the favorable regulatory climate for normal saline products. Regulatory bodies such as the US Food and Drug Administration (FDA) are giving timely approvals to IV solutions to empower hospitals to efficiently deal with emergency health situations and improve patient outcomes.Industry Developments:July 2019: Baxter International received approval from the US FDA for its Insulin Human in 0.9% Sodium Chloride Injection, Myxredlin. The injection is the first and only ready-to-use insulin for IV infusion in health facilities, featuring an extended shelf-life of 30 days at room temperature.January 2018: B. Braun Medical secured clearance for its 0.9% Sodium Chloride Injection, the Ecoflac™ Plus, from the US FDA. With this intravenous solution, B. Braun has expanded its current line of IV options for the administration of normal saline.
List of Key Companies Profiled in this Market Report of Normal Saline for Parenteral Use:Pharmally International Holding Co., Ltd. ( Shangdong, China)Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan)ICU Medical (Illinois, U.S.)Fresenius Kabi AG (Bad Homburg, Germany)Kelun Group (Sichuan, China)Cisen Pharmaceutical Co., Ltd. (Shangdong, China)Double-Crane Pharmaceutical Co., Ltd. (China)B. Braun Melsungen AG (Melsungen, Germany)Baxter (Illinois, U.S.)SSY Group Limited (Hong Kong)
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/normal-saline-for-parenteral-use-market-104520
Table of Contents:IntroductionResearch ScopeMarket SegmentationResearch MethodologyDefinitions and AssumptionsExecutive SummaryMarket DynamicsMarket DriversMarket RestraintsMarket OpportunitiesKey InsightsNumber of Hospital Admissions, By Key Countries/RegionsPrevalence of Key Diseases, By Key Countries/RegionsIV Fluid Shortages in the U.S. – Key ReasonsImpact of COVID-19 on the MarketGlobal Normal Saline for Parenteral Use Market Analysis, Insights and Forecast, 2015-2026Key Findings / SummaryMarket Analysis, Insights and Forecast – By TypePlastic BottlesGlass BottlesMarket Analysis, Insights and Forecast – By ApplicationIntramuscular InjectionIntravenous InjectionMarket Analysis, Insights and Forecast – By RegionNorth AmericaEuropeAsia PacificLatin AmericaMiddle East & Africa
TOC Continued….!
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/normal-saline-for-parenteral-use-market-104520
SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companiesDetails in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facilityNumber of procedures and average price of proceduresReplacement rate and pricing of capital equipmentMarket dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunitiesMarket & technological trends, new product developments, product pipeline.
Have a Look at Related Reports:Alpha-1 antitrypsin deficiency (AATD) Augmentation Therapy Market Share and Global Trend by Product Type (Glassia, Aralast NP, Prolastin C, Zemaira/Respreeza), End User(Hospitals, Specialty Clinics) and Geography Forecast till 2025Glaucoma Therapeutics Market Share and Global Trend By Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Combination Drugs), By Disease Indication (Open Angle Glaucoma, Angle Closure Glaucoma), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2026Orthopedic Joint Replacement Market Share and Global Trend By Product (Knee, Hip, Shoulder, Ankle), By Procedure (Total Replacement, Partial Replacement), By End User (Hospital, Ambulatory Surgical Centers, Orthopedic Clinics) and Geography Forecast till 2026Spinal Cord Stimulation Market Share and Global Trend By Product (Implantable Pulse Generator, Radiofrequency System), Disease Indication (Failed Back Syndrome, Degenerative Disk Disease, Complex Regional Pain Syndrome, Arachnoiditis), End Users (Hospital, Ambulatory Surgical Centers, Specialty Clinics) and Geography Forecast till 2025Retinal Disease Therapeutics Market Share and Global Trend By Disease Indication (Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Retinal Vein Occlusion), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) and Geography Forecast till 2025
About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/global-normal-saline-for-parenteral-use-market-10368

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.